Krishnendu Pal

1.5k total citations
34 papers, 1.2k citations indexed

About

Krishnendu Pal is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Krishnendu Pal has authored 34 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 13 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Krishnendu Pal's work include Pancreatic and Hepatic Oncology Research (5 papers), Angiogenesis and VEGF in Cancer (5 papers) and Renal cell carcinoma treatment (4 papers). Krishnendu Pal is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Angiogenesis and VEGF in Cancer (5 papers) and Renal cell carcinoma treatment (4 papers). Krishnendu Pal collaborates with scholars based in United States, India and Saudi Arabia. Krishnendu Pal's co-authors include Debabrata Mukhopadhyay, Shamit K. Dutta, Enfeng Wang, Vijay Sagar Madamsetty, Ying Cao, Rintu Banerjee‬‬‬‬‬‬‬‬‬, Santanu Bhattacharya, Sutapa Sinha, Dafna Bar‐Sagi and Thomas R. Caulfield and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nano Letters and Gastroenterology.

In The Last Decade

Krishnendu Pal

32 papers receiving 1.1k citations

Peers

Countries citing papers authored by Krishnendu Pal

Since Specialization

Citations

This map shows the geographic impact of Krishnendu Pal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krishnendu Pal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krishnendu Pal more than expected).

Fields of papers citing papers by Krishnendu Pal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krishnendu Pal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krishnendu Pal. The network helps show where Krishnendu Pal may publish in the future.

Co-authorship network of co-authors of Krishnendu Pal

This figure shows the co-authorship network connecting the top 25 collaborators of Krishnendu Pal. A scholar is included among the top collaborators of Krishnendu Pal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krishnendu Pal. Krishnendu Pal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structural and Functional Perspectives of Optineurin in Autophagy, Immune Signaling, and Cancer 2025 ·Cells ·(unknown), (unknown), Shamit K. Dutta, Krishnendu Pal	0
2	Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma 2024 ·Materials Today Bio ·(unknown), (unknown), Ramcharan Singh Angom, (unknown), Shamit K. Dutta, Enfeng Wang, Santanu Bhattacharya, Annadanam V. Sesha Sainath, Hani M. Babiker, Krishnendu Pal, Debabrata Mukhopadhyay	10
3	Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Efficacy and Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma 2024 ·Gastroenterology ·(unknown), (unknown), Ramcharan Singh Angom, Santanu Bhattacharya, Krishnendu Pal, (unknown)	1
4	Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe 2024 ·Journal of Experimental & Clinical Cancer Research ·(unknown), Vijay Sagar Madamsetty, Ramcharan Singh Angom, (unknown), Shamit K. Dutta, Enfeng Wang, (unknown), Krishnendu Pal	7
5	Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma 2022 ·Frontiers in Oncology ·Krishnendu Pal, Tabish Hussain, Hao Xie, (unknown), Ping Yang, Aaron S. Mansfield, Yanyan Lou, Shantanu Chowdhury, Debabrata Mukhopadhyay	5
6	Vascular Endothelial Growth Factor as an Immediate-Early Activator of Ultraviolet-Induced Skin Injury 2021 ·Mayo Clinic Proceedings ·Stella Hartono, Victoria M. Bedell, Sk. Kayum Alam, (unknown), (unknown), (unknown), Krishnendu Pal, Rachel A. Kudgus, Priyabrata Mukherjee, Davis Seelig, Alexander Meves, Debabrata Mukhopadhyay, Stephen C. Ekker, Luke H. Hoeppner	14
7	Dissecting VEGF-induced acute versus chronic vascular hyperpermeability: Essential roles of dimethylarginine dimethylaminohydrolase-1 2021 ·iScience ·Ying Wang, Ramcharan Singh Angom, Tanmay Kulkarni, Luke H. Hoeppner, Krishnendu Pal, Enfeng Wang, (unknown), (unknown), Shamit K. Dutta, Baoan Ji, Natalia Jarzebska, Yingjie Chen, Roman N. Rodionov, Debabrata Mukhopadhyay	2
8	Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer 2020 ·Cancers ·Vijay Sagar Madamsetty, Krishnendu Pal, Shamit K. Dutta, Enfeng Wang, Debabrata Mukhopadhyay	8
9	Development of multi-drug loaded PEGylated nanodiamonds to inhibit tumor growth and metastasis in genetically engineered mouse models of pancreatic cancer 2019 ·Nanoscale ·Vijay Sagar Madamsetty, Krishnendu Pal, Sandeep Keshavan, Thomas R. Caulfield, Shamit K. Dutta, Enfeng Wang, Bengt Fadeel, Debabrata Mukhopadhyay	48
10	Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo 2019 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Douglas O. Faigel, Eduard Sergienko, Andrey A. Bobkov, Nathalie Meurice, Joachim L. Petit, (unknown), Thomas R. Caulfield, Erik P. Castle, John A. Copland, Debabrata Mukhopadhyay, Krishnendu Pal, Shamit K. Dutta, Huijun Luo, Thai H. Ho, Douglas F. Lake	19
11	Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma 2019 ·Bioconjugate Chemistry ·Vijay Sagar Madamsetty, Krishnendu Pal, Shamit K. Dutta, Enfeng Wang, James Thompson, Rintu Banerjee‬‬‬‬‬‬‬‬‬, Thomas R. Caulfield, Kabir Mody, Yun Yen, Debabrata Mukhopadhyay, Hsu‐Shan Huang	16
12	<p>Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC</p> 2019 ·International Journal of Nanomedicine ·Krishnendu Pal, Vijay Sagar Madamsetty, Shamit K. Dutta, Debabrata Mukhopadhyay	40
13	Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer 2019 ·npj Precision Oncology ·Krishnendu Pal, Vijay Sagar Madamsetty, Shamit K. Dutta, Enfeng Wang, Ramcharan Singh Angom, Debabrata Mukhopadhyay	37
14	Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer 2017 ·Nanoscale ·Krishnendu Pal, (unknown), Roberto González-Rodríguez, Shamit K. Dutta, Enfeng Wang, H. Shaun Kwak, Thomas R. Caulfield, Jeffery L. Coffer, Santanu Bhattacharya	52
15	Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth 2014 ·Molecular Cancer Therapeutics ·Krishnendu Pal, Alexandre A. Pletnev, Shamit K. Dutta, Enfeng Wang, Ruizhi Zhao, Aradhita Baral, Vinod Kumar Yadav, Suruchi Aggarwal, Soundararajan Krishnaswamy, Khalid M. Alkharfy, Shantanu Chowdhury, Mark R. Spaller, Debabrata Mukhopadhyay	17
16	Functional genomics of lung cancer progression reveals mechanism of metastasis suppressor function 2014 ·Molecular Cytogenetics ·Ram Krishna Thakur, Vinod Kumar Yadav, Akinchan Kumar, Richa Basundra, Anirban Kar, Rashi Halder, (unknown), Pankaj Kumar, Aradhita Baral, (unknown), Krishnendu Pal, Rintu Banerjee‬‬‬‬‬‬‬‬‬, Shantanu Chowdhury	6
17	Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer 2013 ·Molecular Cancer Therapeutics ·Krishnendu Pal, Ying Cao, Irina N. Gaisina, Santanu Bhattacharya, Shamit K. Dutta, Enfeng Wang, Hendra Gunosewoyo, Alan P. Kozikowski, Daniel D. Billadeau, Debabrata Mukhopadhyay	57
18	VEGF Exerts an Angiogenesis-Independent Function in Cancer Cells to Promote Their Malignant Progression 2012 ·Cancer Research ·Ying Cao, (unknown), Enfeng Wang, Krishnendu Pal, Shamit K. Dutta, Dafna Bar‐Sagi, Debabrata Mukhopadhyay	116
19	A Lipid-Modified Estrogen Derivative that Treats Breast Cancer Independent of Estrogen Receptor Expression through Simultaneous Induction of Autophagy and Apoptosis 2011 ·Molecular Cancer Research ·Sutapa Sinha, (unknown), Bathula Surendar Reddy, Krishnendu Pal, (unknown), Seethalakshmi Iyer, Shamit K. Dutta, Enfeng Wang, Pawan K. Vohra, Karnati R. Roy, Pallu Reddanna, Debabrata Mukhopadhyay, Rintu Banerjee‬‬‬‬‬‬‬‬‬	38
20	Selective Cancer Targeting via Aberrant Behavior of Cancer Cell-associated Glucocorticoid Receptor 2009 ·Molecular Therapy ·(unknown), (unknown), Krishnendu Pal, Jerald Mahesh Kumar, Nandini Rangaraj, Shasi V. Kalivendi, Rintu Banerjee‬‬‬‬‬‬‬‬‬	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact